Evidence map›Paper›PMID 32067625›Full record

Observational studyThe American journal of tropical medicine and hygiene2020

Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.

Edford Sinkala, Michael Vinikoor, Kanekwa Zyambo, Ellen Besa, Bright Nsokolo, Paul Kelly

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review.The American journal of tropical medicine and hygiene · 2023
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Edford SinkalaDepartment of Internal Medicine, University Teaching Hospital, Lusaka, Zambia.
Michael VinikoorCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Kanekwa ZyamboDepartment of Internal Medicine, Tropical Gastroenterology and Nutritional Group, University of Zambia, Lusaka, Zambia.
Ellen BesaDepartment of Internal Medicine, Tropical Gastroenterology and Nutritional Group, University of Zambia, Lusaka, Zambia.
Bright NsokoloDepartment of Internal Medicine, Tropical Gastroenterology and Nutritional Group, University of Zambia, Lusaka, Zambia.
Paul KellyBlizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom.
Tropical Gastroenterology & Nutrition group · ZMUniversity of Zambia · ZMCentre for Infectious Disease Research in Zambia · ZMQueen Mary University of London · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Hepatosplenic schistosomiasis (HSS) complicates portal hypertension, leading to life-threatening variceal bleeding. Variceal bleeding is associated with increased portal vein diameter (PVD). Beta-blockers prevent variceal bleeding. It is unclear whether beta-blockers such as propranolol can reduce PVD in HSS. We aimed to explore the effect of propranolol on PVD in HSS. A longitudinal study was conducted at the University Teaching Hospital, Zambia, as an extension of a clinical trial of rifaximin undertaken to test the hypothesis that rifaximin could reduce bacterial translocation in HSS. We randomized 85 adults to either rifaximin and standard care, or propranolol-based standard care only for 42 days. We then followed up all the patients on propranolol up to day 180. We used ultrasound to measure PVD at baseline and day 180. The primary outcome was reduction in PVD. Beta-blockade and splenic size reduction were secondary outcomes. Portal vein diameter reduced after 180 days of propranolol therapy from median 12 mm (interquartile range (IQR): 11-14) to median 10 mm (IQR: 9-13) (

Indexed as

AdultAnthelminticsAnti-Bacterial AgentsAntihypertensive AgentsFemaleHumansHypertension, PortalLiver DiseasesLongitudinal StudiesMaleMiddle AgedPortal VeinPraziquantelPropranololProspective StudiesRifaximinAnthelminticsAnti-Bacterial AgentsAntihypertensive AgentsPraziquantelPropranololRifaximin

Identifiers

PMID32067625
PMCPMC7124927
OpenAlexW3007400143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.